The ASO gapmers, Inotersen and Volanesorsen are two of the few therapeutics approved that act via RNase H, binding to the transthyretin mRNA (knocking down a defective form of the transcript) and apolipoprotein CIII mRNA, in transthyretin amyloidosis and familial chylomicronemia syndrome respectively [130, 131]. Here, TTR is linked to amyloidosis.